Company intelligence / Profile preview

HanchorBio Inc.

Ownership: Private
Development stage: Clinical

Overview

Lead product HCB101 is in Phase 1/2 clinical trials. It's an engineered SIRPα protein fused to the Fc region of IgG4 that triggers phagocytosis activity of macrophages by blocking the "do not eat me" SIRPα-CD47 signaling pathway. Pre-clinical data suggests it's potentially safer and more potent than anti-CD47 monoclonal antibodies currently in clinical trials[5].

Therapeutic areas: Oncology
Modalities: BiologicsFusion proteinsDesigner biologicsImmune cell therapy
Industry: Biotech

Drug pipeline

5 assets

HCB-101

4 more assets in the full pipeline.

Request access →

Partnerships

Henlius (Shanghai Henlius Biotech Inc.)[3]

Beyond the preview

Go deeper on HanchorBio Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HanchorBio Inc..

Explore the full profile